AstraZeneca PLC (BCBA:AZN)

Market Cap	392.63T
Revenue (ttm)	79.66T
Net Income (ttm)	12.88T
Shares Out	n/a
EPS (ttm)	8,248.60
PE Ratio	30.48
Forward PE	17.76
Dividend	795.69 (1.20%)
Ex-Dividend Date	Aug 8, 2025

Volume	520
Average Volume	334
Open	65,525
Previous Close	65,875
Day's Range	65,325 - 65,975
52-Week Range	34,800 - 67,775
Beta	n/a
RSI	56.83
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD